| Corporate governance and the environment: what type of governance creates greener companies? CJ Kock, J Santaló, L Diestre Journal of Management Studies 49 (3), 492-514, 2012 | 417 | 2012 |
| Are all ‘sharks’ dangerous? new biotechnology ventures and partner selection in R&D alliances L Diestre, N Rajagopalan Strategic Management Journal 33 (10), 1115-1134, 2012 | 388 | 2012 |
| Toward an input-based perspective on categorization: Investor reactions to chemical accidents L Diestre, N Rajagopalan Academy of Management Journal 57 (4), 1130-1153, 2014 | 75 | 2014 |
| An environmental perspective on diversification: The effects of chemical relatedness and regulatory sanctions L Diestre, N Rajagopalan Academy of Management Journal 54 (1), 97-115, 2011 | 73 | 2011 |
| Constraints in acquiring and utilizing directors' experience: An empirical study of new‐market entry in the pharmaceutical industry L Diestre, N Rajagopalan, S Dutta Strategic Management Journal 36 (3), 339-359, 2015 | 64 | 2015 |
| Pushing for speed or scope? Pharmaceutical lobbying and Food and Drug Administration drug review B Barber IV, L Diestre Strategic Management Journal 40 (8), 1194-1218, 2019 | 34 | 2019 |
| Safety crises and R&D outsourcing alliances: Which governance mode minimizes negative spillovers? L Diestre Research Policy 47 (10), 1904-1917, 2018 | 16 | 2018 |
| Why do firms suffer differently from input stigmatization? The costs of removing stigmatized inputs L Diestre, J Santaló Organization Science 31 (1), 47-66, 2020 | 15 | 2020 |
| Can firms avoid tough patent examiners through examiner‐shopping? Strategic timing of citations in USPTO patent applications B Barber IV, L Diestre Strategic Management Journal 43 (9), 1854-1871, 2022 | 14 | 2022 |
| The friday effect: Firm lobbying, the timing of drug safety alerts, and drug side effects L Diestre, B Barber IV, J Santalo Management Science 66 (8), 3677-3698, 2020 | 14 | 2020 |
| When do outside directors create corporate value? J Santaló, L Diestre Available at SSRN 942045, 2006 | 5 | 2006 |
| Response to mason and drakeman's commentary on “fishing for sharks: Partner selection in biopharmaceutical R&D alliances” L Diestre, N Rajagopalan Strategic Management Journal 35 (10), 1566-1568, 2014 | 4 | 2014 |
| Someone else to blame: The effectiveness of egocentric and Alter-centric impression management tactics in the US Food retail industry L Diestre, M Montauti, H Pinto de Sousa Organization Science 34 (3), 1134-1156, 2023 | 3 | 2023 |
| Corporate Governance and the Environment: Bad Discretion, Good Discretion, and Environmental Firm Performance CJ Kock, JS Mediavilla, L Diestre Instituto de Empresa, 2005 | 2 | 2005 |
| Litigate or let it go? Multi-market contact and IP infringement-litigation dynamics L Diestre, F Lumineau, R Durand Research Policy 52 (6), 104784, 2023 | 1 | 2023 |
| Wag the Dog: How embattled corporate leaders use diversionary tactics against shareholder activism TA Dickler, L Diestre Academy of Management Proceedings 2021 (1), 12972, 2021 | 1 | 2021 |
| The ‘Related’Diversification Discount: When Does Related Diversification Destroy Value? L Diestre, J Santalo Academy of Management Proceedings 2013 (1), 12298, 2013 | 1 | 2013 |
| Empirical essays on alliances and innovation in the biopharmaceutical industry L Diestre University of Southern California, 2009 | 1 | 2009 |
| Corporate Governance & the Environment: Bad Discretion, Good Discretion, and Environmental Firm Performance L Diestre, CJ Kock, J Santaló Instituto de Empresa Business School Working Paper No. WP05-24, 2005 | 1 | 2005 |
| Buy Legal or Illegal? How Side-Effect and Medical Malpractice Risks Shape Illegal Pharmacies’ Sales L Diestre, A Fazio, Y Fuentes Academy of Management Proceedings 2023 (1), 14790, 2023 | | 2023 |
Juan SantalóProfessor of Strategic Management at IE UniversityEmail verificata su ie.edu
